Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
Arshad M Khanani Sierra Eye Associates, Reno, NV, USA Purpose: To evaluate the durability of fixed bimonthly dosing of intravitreal aflibercept for neovascular age-related macular degeneration.Methods: Records of 16 patients were retrospectively reviewed. Patients received three initial 2.0&nb...
Enregistré dans:
Auteur principal: | Khanani AM |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2015
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/17cb1875a3cc4faa96fe95312818a81e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration
par: Thomas M, et autres
Publié: (2013) -
Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
par: Garweg JG
Publié: (2019) -
Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab [Corrigendum]
par: Nudleman E, et autres
Publié: (2017) -
Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye
par: Hahn P
Publié: (2014) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
par: Tryfon Rotsos, et autres
Publié: (2010)